NeuBase Therapeutics Inc NBSE:NASDAQ

Last Price$1.05NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.12(12.32%)
Bid (Size)$0.76 (10)
Ask (Size)$1.13 (3)
Day Low / High$0.93 - 1.06
Volume56.8 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022

 

NeuBase Therapeutics Inc ( NASDAQ )

Price: $1.05
Change: +0.12 (12.32%)
Volume: 56.8 K
4:00PM ET 6/30/2022
 
 

Cumberland Pharmaceuticals Inc ( NASDAQ )

Price: $2.08
Change: +0.03 (1.22%)
Volume: 3.9 K
4:00PM ET 6/30/2022
 
 

Mannatech Inc ( NASDAQ )

Price: $16.50
Change: +0.90 (5.77%)
Volume: 3.1 K
1:07PM ET 6/30/2022
 
 

Regulus Therapeutics Inc ( NASDAQ )

Price: $2.07
Change: -0.03 (1.43%)
Volume: 126.5 K
4:00PM ET 6/30/2022
 
 

Adial Pharmaceuticals Inc ( NASDAQ )

Price: $1.34
Change: +0.09 (7.20%)
Volume: 327.1 K
4:00PM ET 6/30/2022
 

Read more news Recent News

--HC Wainwright Adjusts NeuBase Therapeutics' Price Target to $10 From $15, Keeps Buy Rating
8:12AM ET 5/31/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Chardan Capital Adjusts NeuBase Therapeutics' Price Target to $9 from $18, Keeps Buy Rating
10:53AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Decliners
8:10AM ET 4/04/2022 MT Newswires

Curis (CRIS) shares slumped 32% after the company said the US Food and Drug Administration placed the company's leukemia drug on partial clinical hold....

NeuBase Therapeutics Announces Positive Preclinical Data on Myotonic Dystrophy Candidate
3:40AM ET 3/14/2022 MT Newswires

NeuBase Therapeutics (NBSE) on Sunday released new preclinical data for NT-0231.F, which is intended for the treatment of a muscle disorder called myotonic...

Company Profile

Business DescriptionNeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA. View company web site for more details
Address350 Technology Drive
Pittsburgh, Pennsylvania 15219
Phone+1.646.45.1790
Number of Employees3
Recent SEC Filing06/29/20228-K
Chairman & Chief Executive OfficerDietrich A. Stephan
President & Chief Operating OfficerWilliam R. Mann
Chief Financial OfficerTodd P. Branning
Chief Scientific OfficerCurt W. Bradshaw

Company Highlights

Price Open$0.95
Previous Close$0.93
52 Week Range$0.77 - 4.91
Market Capitalization$33.9 M
Shares Outstanding32.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.05
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-67.07%

Analyst Ratings as of 05/27/2022

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset